Open AccessThe delta‐opioid receptor and Parkinson’s disease
Author(s) -
Huang JinZhong,
Ren Yi,
Xu Yuan,
Chen Tao,
Xia Terry C.,
Li ZhuoRi,
Zhao Jiang,
Hua Fei,
Sheng ShiYing,
Xia Ying
Publication year - 2018
Publication title -
cns neuroscience and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 69
eISSN - 1755-5949
pISSN - 1755-5930
DOI - 10.1111/cns.13045
Subject(s) - substantia nigra , pars compacta , dopaminergic , neuroscience , parkinson's disease , basal ganglia , dopamine , medicine , δ opioid receptor , neuroprotection , disease , striatum , psychology , opioid , receptor , central nervous system
Summary Parkinson’s disease (PD) is a common degenerative neurological disease leading to a series of familial, medical, and social problems. Although it is known that the major characteristics of PD pathophysiology are the dysfunction of basal ganglia due to injury/loss of dopaminergic neurons in the substantia nigra pars compacta dopaminergic and exhaustion of corpus striatum dopamine, therapeutic modalities for PD are limited in clinical settings up to date. It is of utmost importance to better understand PD pathophysiology and explore new solutions for this serious neurodegenerative disorder. Our recent work and those of others suggest that the delta‐opioid receptor (DOR) is neuroprotective and serves an antiparkinsonism role in the brain. This review summarizes recent progress in this field and explores potential mechanisms for DOR‐mediated antiparkinsonism.